OBJECTIVE: To probe into the effects of nicorandil combined with clopidogrel on platelet activation indicators and serum brain natriuretic peptide（BNP） and matrix metalloproteinase 9（MMP-9） in patients with acute coronary syndrome（ACS） after percutaneous coronary intervention（PCI）. METHODS: A total of 63 patients with ACS who received PCI in the hospital from Aug. 2020 to Oct. 2021 were extracted to be divided into the control group（n=31） and the observation group（n=32） via the random number table method. The control group was treated with conventional clopidogrel before surgery

and the observation group additionally received nicorandil on the basis of the control group. The platelet activation indicators [CD62 p

CD63 p

platelet aggregation rate（PAR）]

hemodynamic indicators [peak systolic velocit（PSV）

plasma viscosity（PV）

whole blood viscosity（BV）]

serological indicators [BNP

MMP-9

creatine phosphokinase（CK-MB）] and cardiac function indicators [left ventricular end diastolic diameter（LVEDD）

left ventricular end systolic diameter（LVESD）

left ventricular ejection fraction（LVEF）] before surgery and after surgery of 24 h were compared between two groups. RESULTS: After surgery of 24 h

the levels of CD62 p

CD63 p

PAR

PV

BV

BNP

MMP-9

LVEDD and LVESD in two groups were significantly lower than those before surgery

and the above indicators in the observation group were significantly lower than those in the control group

with statistically significant differences（P<0.05）. After surgery of 24 h

the levels of PSV

CK-MB and LVEF in two groups were significantly higher than those before surgery

and the levels of PSV and LVEF in the observation group were significantly higher than those in the control group

while the level of CK-MB was significantly lower than that in the control group

with statistically significant differences（P<0.05）. CONCLUSIONS: Nicorandil combined with clopidogrel can effectively inhibit platelet activation in patients with ACS after PCI

promote the improvement of hemodynamics

reduce the myocardial injury and improve the postoperative cardiac function of patients

with significant clinical application value.